For example, Amodio et al. showed that naked delivery of MALAT1-targeted LNA‐gapmeR (a modified ASO) significantly knocked down MALAT1 in MM cells, with a consequently reduced cell proliferation and bortezomib resistance both in vitro and in vivo (202). Here, MALAT1 is linked to Miyoshi myopathy.